InsiderPulse
Dashboard

CYTK

Cytokinetics, Incorporated

Health CareRussell 2000

Cytokinetics, Incorporated insider trading

Cytokinetics, Incorporated files with the SEC as a Pharmaceutical Preparations company headquartered in South San Francisco, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent CYTK insider transactions

6 insiders traded CYTK on the open market between Jun 15, 2026 and Sep 22, 2026 — 24 sales worth $19.6M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$19.6M

24 of 24 on a 10b5-1 plan

Net
−$19.6M
Insiders
6

Open-market purchases (code P) and sales (code S) from Cytokinetics, Incorporated's own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every CYTK Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

CYTK insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 11 insiders traded CYTK on the open market: 0 purchases and 169 sales worth $61.3M, 150 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 82 sales ($39.1M), by 9 insiders.

QuarterBoughtSold
Q2 2026—−$16.9M25 sales · all on a plan
Q1 2026—−$9.1M22 sales · 12 on a plan
Q4 2025—−$10.6M20 sales · all on a plan
Q3 2025—−$2.5M15 sales · all on a plan
Q2 2025—−$2.9M19 sales · all on a plan
Q1 2025—−$8.2M22 sales · 13 on a plan
Q4 2024—−$3.7M20 sales · all on a plan
Q3 2024—−$7.6M26 sales · all on a plan
Largest sale
−$3.5M of CYTK by Callos Andrew (EVP, Chief Commercial Officer) on Dec 05, 2025, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Malik Fady Ibraham10b5-1

    EVP Research & Development

    −$237.9K

    Jun 09, 2026

    3,500 sh · $67.98

  • Callos Andrew10b5-1

    EVP, Chief Commercial Officer

    −$1.1M

    Jun 01, 2026

    15,000 sh · $74.08

  • Parshall B Lynne10b5-1

    Director

    −$370.4K

    Jun 01, 2026

    5,000 sh · $74.08

  • Kaye Edward M. MD10b5-1

    Director

    −$223.2K

    Jun 01, 2026

    2,933 sh · $76.09

  • Blum Robert I10b5-1

    President & CEO · Director

    −$579.1K

    May 27, 2026

    7,500 sh · $77.21

  • Malik Fady Ibraham10b5-1

    EVP Research & Development

    −$264.9K

    May 19, 2026

    3,500 sh · $75.69

  • Blum Robert I10b5-1

    President & CEO · Director

    −$584.4K

    May 14, 2026

    7,500 sh · $77.92

  • Lee Sung10b5-1

    EVP, Chief Financial Officer

    −$1.8M

    May 05, 2026

    23,906 sh · $76.87

  • Henderson John T10b5-1

    Director

    −$1.5M

    May 05, 2026

    20,000 sh · $75.97

  • Callos Andrew10b5-1

    EVP, Chief Commercial Officer

    −$875.5K

    May 05, 2026

    11,333 sh · $77.25

  • Wierenga Wendell10b5-1

    Director

    −$302.4K

    May 05, 2026

    4,032 sh · $75.00

  • Malik Fady Ibraham10b5-1

    EVP Research & Development

    −$270.8K

    May 05, 2026

    3,500 sh · $77.37

  • Callos Andrew10b5-1

    EVP, Chief Commercial Officer

    −$1M

    May 01, 2026

    15,857 sh · $65.00

  • Callos Andrew10b5-1

    EVP, Chief Commercial Officer

    −$948.9K

    Apr 30, 2026

    15,000 sh · $63.26

  • Blum Robert I10b5-1

    President & CEO · Director

    −$447.2K

    Apr 29, 2026

    7,500 sh · $59.62

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Cytokinetics, Incorporated company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
South San Francisco, CA
Listed on
Nasdaq
SEC Central Index Key
0001061983

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought CYTK

What the stock actually did in the 90 days following each open-market purchase

Don't check CYTK — let it ping you

Get told the moment an insider moves on CYTK

Pro watches Cytokinetics, Incorporated for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add CYTK to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track CYTK on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read CYTK insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

DAWNDYNIMVTINSMIOVAITCIKYMRLEGNMDGLMRUSNUVLPCVX
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are CYTK insiders buying or selling?
Between Jun 15, 2026 and Sep 22, 2026, 6 Cytokinetics, Incorporated insiders made no open-market purchases and 24 sales worth $19.6M, a net sale of $19.6M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much CYTK stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 11 Cytokinetics, Incorporated insiders made no open-market purchases and 169 sales worth $61.3M. 150 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 82 sales ($39.1M). The largest sale was Callos Andrew selling $3.5M on Dec 05, 2025.
What was the largest recent CYTK insider trade?
Blum Robert I (President & CEO · Director) sold $6.8M of CYTK stock on Sep 15, 2026 at about $69.33 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy CYTK shares?
No open-market purchase by a Cytokinetics, Incorporated insider appears in the filings from Jun 15, 2026 to Sep 22, 2026 — every recorded open-market transaction in that period was a sale.
Where does CYTK insider trading data come from?
From the Form 4 filings Cytokinetics, Incorporated's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.